Distribution and Relative Abundance of S100 Proteins in the Brain of the APP23 Alzheimer's Disease Model Mice

被引:28
|
作者
Hagmeyer, Simone [1 ,2 ]
Romao, Mariana A. [3 ]
Cristovao, Joana S. [3 ]
Vilella, Antonietta [4 ]
Zoli, Michele [4 ]
Gomes, Claudio M. [3 ]
Grabrucker, Andreas M. [1 ,5 ,6 ]
机构
[1] Univ Limerick, Dept Biol Sci, Cellular Neurobiol & Neuro Nanotechnol Lab, Limerick, Ireland
[2] Ulm Univ, Neuroctr, Dept Neurol, WG Mol Anal Synaptopathies, Ulm, Germany
[3] Univ Lisbon, Dept Quim & Bioquim, Fac Ciencias, Biosyst & Integrat Sci Inst, Lisbon, Portugal
[4] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Ctr Neurosci & Neurotechnol, Modena, Italy
[5] Univ Limerick, Bernal Inst, Limerick, Ireland
[6] Univ Limerick, Hlth Res Inst, Limerick, Ireland
关键词
S100A8; S100A6; S100B; amyloid beta; cerebellum; aggregates; zinc; MOLECULAR-MECHANISMS; POTENTIAL ROLE; EXPRESSION;
D O I
10.3389/fnins.2019.00640
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increasing evidence links proteins of the S100 family to the pathogenesis of Alzheimer's disease (AD). S100 proteins are EF-hand calcium-binding proteins with intra- and extracellular functions related to regulation of proliferation, differentiation, apoptosis, and trace metal homeostasis, and are important modulators of inflammatory responses. For example, S100A6, S100A8, and S100B expression levels were found increased in inflammatory diseases, but also neurodegenerative disorders, and S100A8/A9 complexes may provide a mechanistic link between amyloid-beta (A beta) plaque formation and neuroinflammation. On the other hand, S100B, a proinflammatory protein that is chronically up-regulated in AD and whose elevation precedes plaque formation, was recently shown to suppress A beta aggregation. Here, we report expression of S100A6 and S100B in astrocytes and less so in neurons, and low level of expression of S100A8 in both neurons and glial cells in vitro. In vivo, S100A8 expression is almost absent in the brain of aged wildtype mice, while S100A6 and S100B are expressed in all brain regions and most prominently in the cortex and cerebellum. S100B seems to be enriched in Purkinje cells of the cerebellum. In contrast, in the brain of APP23 mice, a mouse model for Alzheimer's disease, S100B, S100A6, and S100A8 show co-localization with A beta plaques, compatible with astrocyte activation, and the expression level of S100A8 is increased in neural cells. While S100A6 and S100B are enriched in the periphery of plaques where less fibrillar is found, S100A8 is more intense within the center of the inclusion. In vitro assays show that, similarly to S100B, S100A6, and S100A8 also delay A beta aggregation suggesting a regulatory action over protein aggregation. We posit that elevated expression levels and overlapping spatial distribution of brain S100 proteins and plaques translates functional relationships between these inflammatory mediators and AD pathophysiology processes that uncover important molecular mechanisms linking the aggregation and neuroinflammation cascades.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease
    Hoelscher, Christian
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2011, 39 : 891 - 897
  • [32] Astrocyte S100β expression and selective differentiation to GFAP and GS in the entorhinal cortex during ageing in the 3xTg-Alzheimer's disease mouse model
    Rodriguez, J. J.
    Gardenal, E.
    Zallo, F.
    Arrue, A.
    Cabot, Joan
    Busquets, X.
    ACTA HISTOCHEMICA, 2024, 126 (01)
  • [33] Nrf2 Suppresses Oxidative Stress and Inflammation in App Knock-In Alzheimer's Disease Model Mice
    Uruno, Akira
    Matsumaru, Daisuke
    Ryoke, Rie
    Saito, Ritsumi
    Kadoguchi, Shiori
    Saigusa, Daisuke
    Saito, Takashi
    Saido, Takaomi C.
    Kawashima, Ryuta
    Yamamoto, Masayuki
    MOLECULAR AND CELLULAR BIOLOGY, 2020, 40 (06)
  • [34] The distribution profile and oxidation states of biometals in APP transgenic mouse brain: dyshomeostasis with age and as a function of the development of Alzheimer's disease
    Wang, Huajian
    Wang, Meng
    Wang, Bing
    Li, Ming
    Chen, Hanqing
    Yu, Xiaohan
    Zhao, Yuliang
    Feng, Weiyue
    Chai, Zhifang
    METALLOMICS, 2012, 4 (03) : 289 - 296
  • [35] A New Approach to Model Sporadic Alzheimer's Disease by Intracerebroventricular Streptozotocin Injection in APP/PS1 Mice
    Kelliny, Sally
    Lin, Liying
    Deng, Isaac
    Xiong, Jing
    Zhou, Fiona
    Al-Hawwas, Mohammed
    Bobrovskaya, Larisa
    Zhou, Xin-Fu
    MOLECULAR NEUROBIOLOGY, 2021, 58 (08) : 3692 - 3711
  • [36] Amelioration of Alzheimer's Disease by Gut-Pancreas-Liver-Brain Interaction in an App Knock-In Mouse Model
    Minamisawa, Mayumi
    Sato, Yuma
    Ishiguro, Eitarou
    Taniai, Tetsuyuki
    Sakamoto, Taiichi
    Kawai, Gota
    Saito, Takashi
    Saido, Takaomi C.
    LIFE-BASEL, 2022, 12 (01):
  • [37] Brain hypothyroidism silences the immune response of microglia in Alzheimer's disease animal model
    Kim, Dong Kyu
    Choi, Hyunjung
    Lee, Woochan
    Choi, Hayoung
    Hong, Seok Beom
    Jeong, June-Hyun
    Han, Jihui
    Han, Jong Won
    Ryu, Hoon
    Kim, Jong-Il
    Mook-Jung, Inhee
    SCIENCE ADVANCES, 2024, 10 (11)
  • [38] The role of Aβ and Tau proteins in Alzheimer's disease: a mathematical model on graphs
    Bertsch, Michiel
    Franchi, Bruno
    Tesi, Maria Carla
    Tora, Veronica
    JOURNAL OF MATHEMATICAL BIOLOGY, 2023, 87 (03)
  • [39] Proteins Involved in Endocytosis Are Upregulated by Ageing in the Normal Human Brain: Implications for the Development of Alzheimer's Disease
    Alsaqati, Mouhamed
    Thomas, Rhian S.
    Kidd, Emma J.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2018, 73 (03): : 289 - 298
  • [40] Isolation Housing Exacerbates Alzheimer's Disease-Like Pathophysiology in Aged APP/PS1 Mice
    Huang, Huang
    Wang, Linmei
    Cao, Min
    Marshall, Charles
    Gao, Junying
    Xiao, Na
    Hu, Gang
    Xiao, Ming
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (07) : 1 - 10